Rituximab and obinutuzumab differentially hijack the B-cell receptor and NOTCH1 signaling pathways.

ABSTRACT: An LC-MS/MS based phosphoproteomics study that characterizes the signaling processes downstream of the B-cell receptor and how they are differentially regulated following treatment with anti-CD20 monoclonal antibodies in B-cell lymphoma.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, B-lymphocyte Cell Line, B-lymphocyte

DISEASE(S): B-cell Lymphoma,Diffuse Large B-cell Lymphoma

SUBMITTER: Arran Dokal  

LAB HEAD: Pedro Cutillas

PROVIDER: PXD023572 | Pride | 2021-09-09

REPOSITORIES: Pride